Cyclophosphamide

Generic Name
Cyclophosphamide
Brand Names
Procytox
Drug Type
Small Molecule
Chemical Formula
C7H15Cl2N2O2P
CAS Number
50-18-0
Unique Ingredient Identifier
6UXW23996M
Background

Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication

Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions
Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma
Associated Therapies
-
Clinical Trials
Related News

A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation

First Posted Date
2023-09-21
Last Posted Date
2024-08-09
Lead Sponsor
Celgene
Target Recruit Count
618
Registration Number
NCT06045806
Locations
🇺🇸

Local Institution - 0147, Columbus, Ohio, United States

🇺🇸

Local Institution - 0102, Boston, Massachusetts, United States

🇩🇪

Universitaetsklinikum Carl Gustav Carus Dresden, Dresden, Germany

and more 118 locations

A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination with Radiotherapy (RT) in Relapsed/refractory Follicular Lymphoma

First Posted Date
2023-09-21
Last Posted Date
2024-11-01
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
20
Registration Number
NCT06043323
Locations
🇺🇸

MD Anderson Cancer Center, Houston, Texas, United States

Phase 2 Trial of Epcoritamab in Combination With Rituximab-mini CVP for Older Unfit/Frail Patients or Anthracycline-Ineligible Adult Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma

First Posted Date
2023-09-21
Last Posted Date
2024-08-26
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
40
Registration Number
NCT06045247
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Study of GSK3901961 In Previously Treated Advanced (Metastatic OR Unresectable) Synovial Sarcoma/ Myxoid/Round Cell Liposarcoma, and Previously Treated Metastatic Non-Small Cell Lung Cancer

First Posted Date
2023-09-21
Last Posted Date
2024-11-13
Lead Sponsor
Adaptimmune
Target Recruit Count
7
Registration Number
NCT06048705
Locations
🇸🇪

GSK Investigational Site, Stockholm, Sweden

Rescue of Nephrons With ALE.F02 (RENAL-F02)

First Posted Date
2023-09-21
Last Posted Date
2024-12-20
Lead Sponsor
Alentis Therapeutics AG
Target Recruit Count
80
Registration Number
NCT06047171
Locations
🇩🇪

Universitaetsklinikum Schleswig-Holstein - Campus Luebeck, Luebeck, Germany

🇩🇪

Klinikum der Ludwig-Maximilians-Universitaet Muenchen, München, Germany

🇪🇸

Hospital Regional Universitario de Malaga, Malaga, Spain

and more 45 locations

Dose-Reduced Docetaxel With Cyclophosphamide for the Treatment of Vulnerable Older Women With Stage I-III HER2 Negative Breast Cancer, the DOROTHY Trial

First Posted Date
2023-09-18
Last Posted Date
2024-10-02
Lead Sponsor
City of Hope Medical Center
Target Recruit Count
174
Registration Number
NCT06042569
Locations
🇺🇸

City of Hope Medical Center, Duarte, California, United States

🇺🇸

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma

First Posted Date
2023-09-07
Last Posted Date
2024-04-29
Lead Sponsor
Marcela V. Maus, M.D.,Ph.D.
Target Recruit Count
24
Registration Number
NCT06026319
Locations
🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis

First Posted Date
2023-09-05
Last Posted Date
2024-07-08
Lead Sponsor
SWOG Cancer Research Network
Target Recruit Count
338
Registration Number
NCT06022939
Locations
🇺🇸

Boston Medical Center, Boston, Massachusetts, United States

🇺🇸

Washington University School of Medicine, Saint Louis, Missouri, United States

🇺🇸

Siteman Cancer Center-South County, Saint Louis, Missouri, United States

and more 32 locations

Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease

First Posted Date
2023-09-05
Last Posted Date
2024-08-27
Lead Sponsor
St. Jude Children's Research Hospital
Target Recruit Count
100
Registration Number
NCT06023641
Locations
🇺🇸

Cook Children's Medical Center, Fort Worth, Texas, United States

🇺🇸

Sanford University, Palo Alto, California, United States

🇺🇸

St. Jude Children's Research Hospital, Memphis, Tennessee, United States

A Study of TCD601 in the Induction of Tolerance in de Novo Liver Transplantation

First Posted Date
2023-08-31
Last Posted Date
2024-11-27
Lead Sponsor
ITB-Med LLC
Target Recruit Count
12
Registration Number
NCT06019507
Locations
🇸🇪

Karolinska University Hospital, Stockholm, Huddinge, Sweden

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy